CY1107506T1 - Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης - Google Patents

Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης

Info

Publication number
CY1107506T1
CY1107506T1 CY20071101368T CY071101368T CY1107506T1 CY 1107506 T1 CY1107506 T1 CY 1107506T1 CY 20071101368 T CY20071101368 T CY 20071101368T CY 071101368 T CY071101368 T CY 071101368T CY 1107506 T1 CY1107506 T1 CY 1107506T1
Authority
CY
Cyprus
Prior art keywords
compounds
stabilization
venzimidazola
union
physiologically acceptable
Prior art date
Application number
CY20071101368T
Other languages
English (en)
Inventor
Koji Ukai
Satoshi Fujioka
Mitsuru Mizuno
Makoto Yokoyama
Shigeru Aoki
Masao Kawamura
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CY1107506T1 publication Critical patent/CY1107506T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια μέθοδο για σταθεροποίηση στοματικών στερεών παρασκευών που περιέχουν ενώσεις βενζιμιδαζόλης ή φυσιολογικά αποδεκτά άλατα τους. Ειδικότερα, μια μέθοδο για σταθεροποίηση ενώσεων βενζιμιδαζόλης ή φυσιολογικά αποδεκτών αλάτων τους, που χαρακτηρίζεται από την ανάμειξη των ενώσεων ή των αλάτων τους με 1) κροσποβιδόνη και, εάν χρειάζεται, (2) υδροξείδιο του νατρίου και/ή υδροξείδιο του καλίου.
CY20071101368T 1999-10-20 2007-10-24 Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης CY1107506T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29806399 1999-10-20
EP00969905A EP1222922B1 (en) 1999-10-20 2000-10-19 Method for stabilizing benzimidazole compounds

Publications (1)

Publication Number Publication Date
CY1107506T1 true CY1107506T1 (el) 2013-03-13

Family

ID=17854666

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101368T CY1107506T1 (el) 1999-10-20 2007-10-24 Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης

Country Status (19)

Country Link
US (1) US7220762B1 (el)
EP (1) EP1222922B1 (el)
JP (1) JP4081273B2 (el)
KR (1) KR20020038759A (el)
CN (1) CN1197574C (el)
AT (1) ATE369857T1 (el)
AU (1) AU782538B2 (el)
CA (1) CA2387746C (el)
CY (1) CY1107506T1 (el)
DE (1) DE60036014T2 (el)
DK (1) DK1222922T3 (el)
ES (1) ES2288876T3 (el)
HU (1) HU229213B1 (el)
MX (1) MXPA02003762A (el)
NO (1) NO329940B1 (el)
PT (1) PT1222922E (el)
RU (1) RU2259828C2 (el)
TW (1) TWI268779B (el)
WO (1) WO2001028559A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1141097C (zh) * 1998-04-20 2004-03-10 卫材株式会社 含有稳定化的苯并咪唑类化合物的组合物
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
KR20050044545A (ko) * 2001-11-21 2005-05-12 에자이 가부시키가이샤 산에 불안정한 생리활성 화합물을 함유하는 제제 조성물및 그 제법
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
EP1518240B1 (en) 2002-06-28 2014-05-07 LG Electronics, Inc. Recording medium having data structure for managing recording and reproduction of multiple path data recorded thereon and recording and reproducing methods and apparatus
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
BRPI0509135A (pt) * 2004-03-26 2007-08-28 Eisai R&D Man Co Ltd composição farmacêutica de liberação controlada e método para produzir a mesma
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JPWO2007037259A1 (ja) * 2005-09-29 2009-04-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 生体内での崩壊性を向上させたパルス製剤
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
CN100411613C (zh) * 2006-12-08 2008-08-20 中国药科大学 一种奥美拉唑速释固体制剂及其制备方法
WO2008129517A2 (en) * 2007-04-23 2008-10-30 Ranbaxy Laboratories Limited A stabilized delayed release pharmaceutical composition of rabeprazole
JP5399749B2 (ja) * 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
WO2014016754A2 (en) * 2012-07-26 2014-01-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
RU2554735C1 (ru) * 2014-08-20 2015-06-27 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая рабепразол натрия, и способ ее получения
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB189698A (en) 1921-12-29 1922-12-07 Miniere & Ind Franco Bresilien Method for the treatment of monazite and other phosphate ores
US4471638A (en) * 1982-03-26 1984-09-18 Steelcase Inc. Front removable lock
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
ZA871177B (en) 1986-02-21 1988-10-26 Nihon Nohyaku Co Ltd 1,3-diketone derivatives and their use
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
AU619444B2 (en) 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
JPH0656665A (ja) * 1992-08-03 1994-03-01 Nippon Chemiphar Co Ltd イミダゾール誘導体を含有する胃溶性抗潰瘍剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
DK0723436T3 (da) 1994-07-08 2001-11-26 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5708017A (en) 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
ES2236628T3 (es) * 1995-09-21 2005-07-16 Pharma Pass Ii Llc Composicion farmaceutica que contiene un omeprazol labil de acido, y procedimiento para su preparacion.
BE1009764A3 (nl) 1995-11-06 1997-08-05 Dsm Nv Werkwijze voor de bereiding van een alpha-alkylkaneelaldehyde.
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
JPH09216817A (ja) 1996-02-08 1997-08-19 Amano Pharmaceut Co Ltd 防湿性且つ易水崩壊性コーティング製剤
ATE220543T1 (de) 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
EP0923577A2 (en) 1996-06-25 1999-06-23 Takeda Chemical Industries, Ltd. Oxazolone derivatives and their use as anti-helicobacter pylori agent
GB9710800D0 (en) * 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
TW580397B (en) 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
SE9702000D0 (sv) 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6296876B1 (en) 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US20050244497A1 (en) 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
CN1141097C (zh) 1998-04-20 2004-03-10 卫材株式会社 含有稳定化的苯并咪唑类化合物的组合物
ZA9810765B (en) 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same

Also Published As

Publication number Publication date
MXPA02003762A (es) 2002-09-30
HUP0203333A3 (en) 2004-01-28
ATE369857T1 (de) 2007-09-15
AU7950200A (en) 2001-04-30
CN1197574C (zh) 2005-04-20
AU782538B2 (en) 2005-08-04
WO2001028559A1 (fr) 2001-04-26
NO329940B1 (no) 2011-01-24
RU2259828C2 (ru) 2005-09-10
HUP0203333A2 (hu) 2003-02-28
DK1222922T3 (da) 2007-12-03
CA2387746C (en) 2010-06-29
NO20021875L (no) 2002-06-04
DE60036014T2 (de) 2008-04-30
DE60036014D1 (de) 2007-09-27
EP1222922A1 (en) 2002-07-17
KR20020038759A (ko) 2002-05-23
EP1222922B1 (en) 2007-08-15
EP1222922A4 (en) 2006-04-12
JP4081273B2 (ja) 2008-04-23
ES2288876T3 (es) 2008-02-01
US7220762B1 (en) 2007-05-22
NO20021875D0 (no) 2002-04-19
CN1382049A (zh) 2002-11-27
CA2387746A1 (en) 2001-04-26
HU229213B1 (en) 2013-09-30
TWI268779B (en) 2006-12-21
PT1222922E (pt) 2007-09-12

Similar Documents

Publication Publication Date Title
CY1107506T1 (el) Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης
CY1113609T1 (el) ΔΙΑΛΥΤΟΤΗΤΑ ΙFΝ-ΒΗΤΑ-1b ΣΕ ΔΙΑΛΥΜΑΤΑ ΧΛΩΡΙΟΥΧΟΥ ΝΑΤΡΙΟΥ
ATE526022T1 (de) Stabilisierte zusammenstellungen die benzimidazole enthalten
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
CO5210911A1 (es) Trifluorbutenos nematicidas
ATE316083T1 (de) Adamantanderivate
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
TR199701647A2 (xx) �kame edilmi� purin t�revleri,bunlar�n imalat usul�
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
CY1105235T1 (el) Συνθεσεις λασοφοξιφενης
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
CY1106633T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν χαλκο, σαλικυλικο οξυ και βιταμινη c
TR200001452T2 (tr) Bifenilamidin türevleri.
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
MXPA03008736A (es) Derivados de (p-aminohidroxifenil)acrilamida y colorantes que contienen dichos compuestos.
EA200101150A1 (ru) Раствор прукалоприда для перорального применения
BR9708280A (pt) Compostos de inclusão de diclofenaco/gama-cd
SE9902742D0 (sv) New pharmaceutical formultion